New virus combo tackles liver metastases in colorectal cancer

NCT ID NCT06283134

Not yet recruiting Disease control Sponsor: China Medical University, China Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new approach for people with colorectal cancer that has spread to the liver and hasn't responded to standard treatments. It combines a virus designed to attack cancer cells (BioTTT001) with two drugs (toripalimab and regorafenib). The study will enroll 60 participants to check safety and find the best dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: oncolytic adenovirus (BioTTT001) plus toripalimab and regorafenib
What this could lead to: If successful, this could point toward a new combination treatment for colorectal cancer that has spread to the liver, potentially improving survival.
What could go wrong: This is an early Phase 1 trial with only 60 participants, so safety and dosing are still being explored. The treatment may not work or could cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER METASTATIC

More trials for these conditions

Other studies related to the condition(s) this trial covers.